exenatide ER
Selected indexed studies
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. (Diabetes Care, 2018) [PMID:29246950]
- Exenatide ER-induced eosinophilia. (Am J Health Syst Pharm, 2020) [PMID:32470112]
- Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models. (Aging (Albany NY), 2020) [PMID:32392536]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. (2021) pubmed
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. (2018) pubmed
- Exenatide ER-induced eosinophilia. (2020) pubmed
- Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models. (2020) pubmed
- Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. (2021) pubmed
- [Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]. (2025) pubmed
- Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes. (2014) pubmed
- Assessment of Exenatide Extended-Release for Maintenance of Diabetic Remission in Cats. (2025) pubmed
- Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus. (2015) pubmed
- Exenatide extended-release: a review of its use in type 2 diabetes mellitus. (2012) pubmed